Inaguma D, et al. - This study was conducted to assess the impact of a combination therapy with renin-angiotensin system blockers (RASBs) and vitamin D receptor activators (VDRAs) on the incidence of cardiovascular (CV) events in dialysis patients. Findings demonstrated that combination therapy with RASBs and VDRAs in patients before dialysis initiation was related to reduced CV events during maintenance dialysis.